ClinicalTrials.gg
Active, not recruitingNCT04253015Updated Oct 26, 2026

A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

An observational study in Neuroblastoma, sponsored by RECORDATI GROUP. Active, not recruiting at 13 sites in 7 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by RECORDATI GROUP · Observational

How we know

Updated Oct 26, 2026Now Active, not recruitingTitle changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Neuroblastoma with a site in France — 10 open to participants now, 15 under way, 2 of them phase 3. Neuroblastoma · France.

Started
2019
with 2 others
Observational
4 of 54
3 open now
Primary completion
2036-06
later than 13 of 14 live
Registered
43rd of 54
by date

Among the 54 studies in Neuroblastoma with a site in France, this one is one of 3 that started in 2019, is one of 4 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 43rd registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

10 of the 54 studies in Neuroblastoma with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Neuroblastoma with a site in France, or all of them as a file.
02

Study summary

This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

Read the detailed description

Rationale and Background:

Neuroblastoma, is the most common extra-cranial solid tumour in children. Most patients with neuroblastoma are diagnosed under the age of 5 years and most present with metastatic disease and/or high-risk features. Despite the introduction of novel treatment strategies, including high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), the outcome of these patients remains poor.

Dinutuximab beta is a chimeric monoclonal immunoglobulin G 1 (IgG1) antibody that is specifically directed against the carbohydrate moiety of disialoganglioside antigen (GD2), which is overexpressed on neuroblastoma cells. By binding to neuroblastoma cells, dinutuximab beta can induce both complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).

The efficacy of dinutuximab beta has been evaluated in a randomised controlled trial comparing the administration of dinutuximab beta with or without interleukin 2 (IL-2) in the first-line treatment of patients with high-risk neuroblastoma and in two singlearm studies in the relapsed/refractory setting. The efficacy and safety of dinutuximab beta will further be evaluated in this registry that will provide information on survival, pain severity and incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

Study Design:

This is a non-interventional, multi-national, observational, prospective patient registry of patients with high-risk neuroblastoma being treated with the monoclonal antibody dinutuximab beta. The efficacy and safety of dinutuximab beta will further be evaluated in this registry that will provide information on survival, pain severity and incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

Research Questions and Objectives:

Primary objectives:

  • To assess pain severity and use of analgesics during the period of first dose of dinutuximab beta to end of last 35 day course of the 5th cycle of treatment
  • To assess the incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions
  • To assess the long term safety profile

Secondary objectives:

  • Progression free survival (PFS) in patients treated with dinutuximab beta.
  • Event Free Survival (EFS) in patients treated with dinutuximab beta
  • Overall survival (OS) in patients treated with dinutuximab beta

Population:

Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab beta in the standard clinical practice setting or participating in a clinical trial where dinutuximab beta is provided according to the indication as per the country/regional marketing authorisation, provide consent/assent and are willing to be followed up for up to 10 years.

Study Size:

It is planned to enroll a sufficient number of patients (estimated at 125) such that 100 patients will have completed all five treatment courses of dinutuximab beta. It is anticipated that this will result in 40-50 patients who are progression free at 10 years.

Data Sources:

Data will be collected from physicians using an electronic data capture (EDC) system. The electronic case report forms (eCRFs) will be designed to gather data from the medical records at baseline, during treatment and at normal clinical practice follow up visits.

Data Analysis:

The safety analysis set, containing all patients treated with at least one dose of dinutuximab beta will be considered for safety and efficacy analyses. All baseline, treatment period and follow up characteristics will be summarized using descriptive statistics. Endpoints addressing primary and secondary analysis will include 95% confidence intervals (CIs) including the Clopper Pearson method for binomial, log-log transform for survival. OS, PFS and EFS will be analysed using Kaplan-Meier methods.

Variables:

Baseline (prior to start of treatment): Demographics, clinical trial participation, neuroblastoma disease history, and presence or absence of neurotoxicity, visual impairment, and cardiovascular abnormality.

Treatment period (up to end of last 35 day course of 5th cycle of treatment):

Dosing regimen, total cumulative amount of dinutuximab beta per course, concomitant medications during course (IL-2, retinoic acid and/or antihistamines), daily analgesics (opioids, gabapentin/ pregabalin and/or non-opioid analgesics and other neuropathic pain treatments), daily pain assessment during infusion of dinutuximab beta, occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, and hypersensitivity reactions, adverse events (AEs)/serious adverse events (SAEs) treatment interruptions and discontinuations, progression of disease, date and cause of death, reason for study withdrawal (if applicable) Follow up (from end of last 35 day course of 5th cycle of treatment): Status of neurotoxicity, visual impairment, cardiovascular events, (resolved, not resolved), SAEs and adverse drug reaction (ADRs), progression of disease, date and cause of death, reason for study withdrawal (if applicable).

03

Conditions studied

  • Neuroblastoma

Keywords

  • Tumour
  • Brain tumour
  • Paediatrics
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab beta in the standard clinical practice setting or participating in a clinical trial where dinutuximab beta is provided according to the indication as per the country/regional marketing authorisation, provide consent/assent and are willing to be followed up for up to 10 years. Centers who treat neuroblastoma patients with dinutuximab beta will be invited to participate in the registry. This includes networks such as the Society of Paediatric Oncology for the Treatment of Neuroblastoma (SIOPEN) in Europe.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients meeting the following criteria will be considered for inclusion into the registry:

  • Patients diagnosed with high-risk neuroblastoma and starting treatment with commercially available dinutuximab beta OR
  • Patients diagnosed with high-risk neuroblastoma and starting treatment with dinutuximab beta in a clinical trial where dinutuximab beta is provided according to the country/regional marketing authorisation AND
  • Appropriate consent/assent has been obtained for participation in the registry with a willingness to be followed up for up to 10 years.

Exclusion criteria

Exclusion Criteria:

Patient will not be eligible for inclusion if the following criterion applies:

  • Patients commencing dinutuximab beta within a clinical trial where the product is being provided outside of the country/regional marketing authorisation OR
  • Appropriate consent/assent has not been obtained for participation in the registry or patient/legal representative is not willing for the patient be followed up for up to 10 years.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (actual)
Target follow-up
10 Years
Patient registry
Yes

Interventions

  • OtherData-collection

    Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.

06

What researchers measure

Primary outcomes

  1. Assessment of the severity of pain experienced by participants during treatment with dinutuximab beta

    Assessment of pain severity experienced by participants during the period of first dose of dinutuximab beta to the end of last 35 day course of 5th cycle of treatment

    Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

  2. Number of participants using analgesics during treatment with dinutuximab beta

    Use of analgesics during the period of first dose of dinutuximab beta to end of last 35 day course of 5th cycle of treatment

    Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

  3. Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions

    Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions up to the end of the last 35 day course of 5th cycle of treatment

    Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

  4. Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) during treatment with dinutuximab beta

    Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) following the end of the last 35 day course of 5th cycle of treatment

    Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) following the end of the last 35 day course of 5th cycle of treatment

    Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

  2. Progression free survival (PFS)

    Progression free survival (PFS) following the end of the last 35 day course of 5th cycle of treatment

    Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

  3. Event Free Survival (EFS)

    Event Free Survival (EFS) following the end of the last 35 day course of 5th cycle of treatment

    Time frame: First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Jun 2036, 201 months after the start.

Of 34 observational studies under Neuroblastoma, half reached primary completion within 213 months of starting (the median), counting those still running; a quarter within 74 and three quarters within 304. This study's planned 201 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Mar 2032 → Jun 2036 and completion Jun 2032 → Jun 2036.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Feb 5, 2020
StartActual
Sep 30, 2019
Primary completionEst.
Jun 30, 2036was Mar 2032
CompletionEst.
Jun 30, 2036was Jun 2032
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 9, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (1 Austria, 1 Poland, 1 Spain, 1 United Kingdom)
  • St. Anna Kinderkrebsforschung · Vienna, Austria
  • Uniwersytecki Szpital Dziecięcy · Krakow, Poland
  • Vall d'Hebron University Hospital · Barcelona, Spain
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust · Newcastle upon Tyne, United Kingdom
Show 4 removed
  • St. Anna Kinderkrebsforschung · Wien,, Austria
  • Institut Curie · Paris, France
  • Uniwersytecki Szpital Dziecięcy · Kraków, Poland
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust · Newcastle Upon Tyne, United Kingdom
Oct 9, 2026
Primary completion
Mar 31, 2032→Jun 30, 2036
Oct 9, 2026
Study completion
Jun 15, 2032→Jun 30, 2036
Oct 9, 2026
Title
A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Title A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
  2. Oct 9, 2026
    Recruiting→Active, not recruiting
    4 sites added, 4 sites removed
    Show 4 added (1 Austria, 1 Poland, 1 Spain, 1 United Kingdom)
    • St. Anna Kinderkrebsforschung · Vienna, Austria
    • Uniwersytecki Szpital Dziecięcy · Krakow, Poland
    • Vall d'Hebron University Hospital · Barcelona, Spain
    • The Newcastle upon Tyne Hospitals NHS Foundation Trust · Newcastle upon Tyne, United Kingdom
    Show 4 removed
    • St. Anna Kinderkrebsforschung · Wien,, Austria
    • Institut Curie · Paris, France
    • Uniwersytecki Szpital Dziecięcy · Kraków, Poland
    • The Newcastle upon Tyne Hospitals NHS Foundation Trust · Newcastle Upon Tyne, United Kingdom
    Primary completion Mar 31, 2032→Jun 30, 2036
    Study completion Jun 15, 2032→Jun 30, 2036
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04253015
Lead sponsor
RECORDATI GROUP
Collaborators
United BioSource, LLC
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Sep 30, 2019
Primary completion
Jun 30, 2036 (estimated)
Completion
Jun 30, 2036 (estimated)
Last update
Oct 26, 2026

Study contacts

Ignacio Alvarez
study director · EUSA Pharma (UK) Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion